The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
Status:
Terminated
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This study tests the effects of an experimental drug PC945 in people with asthma or other
chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida
yeasts.
PC945 may be useful in treating patients infected with Aspergillus as, unlike the usual
treatments, it is inhaled into the lung and has been designed to stay there and treat the
infection. Participants will continue to receive their usual treatment for their chronic
respiratory disease. Half of the participants will receive PC945 and half will receive a
placebo. The amount of fungus and yeast in the patients' phlegm will be measured over the
course of the study. The study will take place at multiple sites in UK and will include
approximately 46 participants. The maximum study duration will be about 16 weeks.